Targeting Glucose Metabolism: An Emerging Concept for Anticancer Therapy

Mortality from locally advanced and metastatic cancer remains high despite advances in our understanding of the molecular basis of the disease and improved adjuvant therapies. Recently, there has been an increased interest in cancer metabolomics, and in particular, the potential for targeting glucose metabolism, for therapeutic gain. This interest stems from the fact that cancer cells metabolize glucose very differently from normal cells. Cancer cells preferentially switch to aerobic glycolysis rather than oxidative phosphorylation as their means of glucose metabolism. This metabolic switch is believed to enhance cancer cell survival. Several therapeutic agents that target tumor metabolism have shown significant cancer cell cytotoxicity in preclinical studies, and some have progressed to clinical trials. In this review, we discuss the alteration of carbohydrate metabolism seen in cancer cells, the underlying mechanisms, and opportunities for targeting cancer metabolism for therapeutic purposes.

[1]  N. Savaraj,et al.  Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). , 2002, Biochemical pharmacology.

[2]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[3]  B. Teicher,et al.  Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro , 2004, Cancer Chemotherapy and Pharmacology.

[4]  P. Sutphin,et al.  Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy , 2007, Proceedings of the National Academy of Sciences.

[5]  Jong-Wan Park,et al.  A domain responsible for HIF-1α degradation by YC-1, a novel anticancer agent , 2006 .

[6]  R. Shoemaker,et al.  Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts , 2004, Cancer Research.

[7]  T. Bruno,et al.  Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. , 1998, Biochemical pharmacology.

[8]  G. Semenza HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. , 2009, Current pharmaceutical design.

[9]  Y. J. Sun,et al.  The crystal structure of a multifunctional protein: phosphoglucose isomerase/autocrine motility factor/neuroleukin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  T. Hunter,et al.  Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[11]  M Cascante,et al.  The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. , 2001, European journal of biochemistry.

[12]  Ching-Shyang Chen,et al.  Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells , 2010, Breast Cancer Research and Treatment.

[13]  Divya Pathania,et al.  Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. , 2009, Advanced drug delivery reviews.

[14]  G. Melillo,et al.  Development of HIF-1 inhibitors for cancer therapy , 2009, Journal of cellular and molecular medicine.

[15]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[16]  G. Hart,et al.  Glycobiology and Cancer: Meeting Summary and Future Directions , 2004, Cancer biology & therapy.

[17]  P. Pedersen The cancer cell’s “power plants” as promising therapeutic targets: An overview , 2007, Journal of bioenergetics and biomembranes.

[18]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[19]  Jun O. Liu,et al.  Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth , 2008, Proceedings of the National Academy of Sciences.

[20]  Xiaojun Xu,et al.  Transketolase‐like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells , 2009, International journal of cancer.

[21]  Martin G Pomper,et al.  Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. , 2004, Biochemical and biophysical research communications.

[22]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[23]  Hiroshi Yamamoto,et al.  Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer. , 1996, British Journal of Cancer.

[24]  A. Harris,et al.  Targeting the hypoxia-inducible factor (HIF) pathway in cancer , 2009, Expert Reviews in Molecular Medicine.

[25]  P. Bottoni,et al.  Glycolytic enzyme inhibitors in cancer treatment. , 2008, Expert opinion on investigational drugs.

[26]  A. Alavi,et al.  Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.

[27]  Yinfeng Yang,et al.  A new G6PD knockdown tumor-cell line with reduced proliferation and increased susceptibility to oxidative stress. , 2009, Cancer biotherapy & radiopharmaceuticals.

[28]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[29]  R. Wahl,et al.  Targeting of VX2 Rabbit Liver Tumor by Selective Delivery of 3-Bromopyruvate: A Biodistribution and Survival Study , 2008, Journal of Pharmacology and Experimental Therapeutics.

[30]  G. Paine-Murrieta,et al.  Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α , 2004, Molecular Cancer Therapeutics.

[31]  Min Wu,et al.  Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. , 2007, American journal of physiology. Cell physiology.

[32]  Y. Liu,et al.  Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.

[33]  A. Raz,et al.  Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. , 1998, Cancer research.

[34]  Jing Chen,et al.  Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth , 2009, Science Signaling.

[35]  Awtar Krishan,et al.  Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions , 2004, Cancer Chemotherapy and Pharmacology.

[36]  Robert A. Harris,et al.  Pyruvate Dehydrogenase Complex Activity Controls Metabolic and Malignant Phenotype in Cancer Cells* , 2008, Journal of Biological Chemistry.

[37]  K. Greulich,et al.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. , 2004, Genomics.

[38]  N. Savaraj,et al.  2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo , 2004, Cancer Research.

[39]  B. Dwarakanath,et al.  Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. , 1996, International journal of radiation oncology, biology, physics.

[40]  G. Semenza,et al.  HIF-1 mediates the Warburg effect in clear cell renal carcinoma , 2007, Journal of bioenergetics and biomembranes.

[41]  Saroj P. Mathupala,et al.  Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria , 2006, Oncogene.

[42]  W. Linehan,et al.  LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer , 2009, Molecular Cancer Therapeutics.

[43]  J. Pouysségur,et al.  MAP Kinases and Hypoxia in the Control of VEGF Expression , 2004, Cancer and Metastasis Reviews.

[44]  Ru Wei,et al.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.

[45]  T. Lazar Mathew,et al.  Optimizing Cancer Radiotherapy with 2-Deoxy-D-Glucose , 2005, Strahlentherapie und Onkologie.

[46]  A. Yalçin,et al.  Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. , 2009, Experimental and molecular pathology.

[47]  A. Eberle,et al.  TT232, A Novel Signal Transduction Inhibitory Compound in the Therapy of Cancer and Inflammatory Diseases , 2005, Journal of receptor and signal transduction research.

[48]  J. von Pawel,et al.  Phase III trial with and without lonidamine in non-small cell lung cancer. , 1991, Seminars in oncology.

[49]  R. Sun,et al.  Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo , 2010, Breast Cancer Research and Treatment.

[50]  Takashi Uehara,et al.  Koningic Acid (a Potent Glyceraldehyde‐3‐Phosphate Dehydrogenase Inhibitor)‐Induced Fragmentation and Condensation of DNA in NG108‐15 Cells , 1997, Journal of neurochemistry.

[51]  P. Bruzzi,et al.  Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Y. Pommier,et al.  Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1 , 2004, Cancer Research.

[53]  F. Kuhajda,et al.  Fatty acid synthase and cancer: new application of an old pathway. , 2006, Cancer research.

[54]  Laura C. Greaves,et al.  Mitochondrial DNA mutations in human disease , 2006, IUBMB life.

[55]  W. Evans,et al.  Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. , 2009, Blood.

[56]  B. Dwarakanath,et al.  Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells , 2005, International journal of radiation biology.

[57]  R. Wittig,et al.  Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. , 2008, American journal of clinical pathology.

[58]  B. Silvestrini,et al.  Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. , 1981, Journal of the National Cancer Institute.

[59]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[60]  H. Chen,et al.  Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer , 2009, Journal of experimental & clinical cancer research : CR.

[61]  O. Nanni,et al.  Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial , 1998, Breast Cancer Research and Treatment.

[62]  G. Semenza Hypoxia-inducible factor 1: master regulator of O2 homeostasis. , 1998, Current opinion in genetics & development.

[63]  R. Shoemaker,et al.  Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition , 2009, Molecular Cancer Therapeutics.

[64]  M. Cascante,et al.  Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle , 1999, FEBS letters.

[65]  N. Munshi,et al.  Dichloroacetate induces apoptosis in endometrial cancer cells. , 2008, Gynecologic oncology.

[66]  A. Gadducci,et al.  Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. , 1994, European journal of cancer.

[67]  Sébastien Bonnet,et al.  A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.

[68]  Chi V Dang,et al.  Multifaceted roles of glycolytic enzymes. , 2005, Trends in biochemical sciences.

[69]  P. Pedersen,et al.  Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen , 2007, Journal of bioenergetics and biomembranes.

[70]  A. Scarpa,et al.  An integrated humoral and cellular response is elicited in pancreatic cancer by α‐enolase, a novel pancreatic ductal adenocarcinoma‐associated antigen , 2009, International journal of cancer.

[71]  P. Pacini,et al.  FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results. , 2000, European journal of cancer.

[72]  A. Giatromanolaki,et al.  PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer , 2008, British Journal of Cancer.

[73]  S. Kaufmann,et al.  6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  M. Guida,et al.  Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. , 2001, European journal of cancer.

[75]  A. Lane,et al.  Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation , 2007, Molecular Cancer Therapeutics.

[76]  Laurent Schwartz,et al.  Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice. , 2009, Anticancer research.

[77]  Marta Cascante,et al.  Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29 , 2009, International journal of cancer.

[78]  John O Trent,et al.  Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.

[79]  M. Knopp,et al.  Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor , 2008, Clinical Cancer Research.

[80]  C. Hew,et al.  Proteomic Analysis of Colorectal Cancer Reveals Alterations in Metabolic Pathways , 2006, Molecular & Cellular Proteomics.

[81]  R. Wahl,et al.  Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer , 2009, Investigational New Drugs.

[82]  N. Savaraj,et al.  Differential Sensitivity to 2-Deoxy-D-glucose Between Two Pancreatic Cell Lines Correlates With GLUT-1 Expression , 2005, Pancreas.

[83]  N. Savaraj,et al.  Hypersensitization of tumor cells to glycolytic inhibitors. , 2001, Biochemistry.

[84]  P. Auberger,et al.  Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells. , 2009, Cancer research.

[85]  C. Dang,et al.  Oncogenic alterations of metabolism and the Warburg effect , 2005 .

[86]  O. Warburg [Origin of cancer cells]. , 1956, Oncologia.

[87]  G. Kéri,et al.  A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models. , 2006, Anticancer research.

[88]  Jong-Wan Park,et al.  A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. , 2006, International journal of oncology.

[89]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[90]  R. Deberardinis,et al.  The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation , 2005, Oncogene.

[91]  L. Leng,et al.  High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. , 2002, Cancer research.

[92]  Jinho Kim,et al.  YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. , 2003, Journal of the National Cancer Institute.

[93]  Oksana Gavrilova,et al.  p53 Regulates Mitochondrial Respiration , 2006, Science.

[94]  V. Hogan,et al.  Down-regulation of Phosphoglucose Isomerase/Autocrine Motility Factor Expression Sensitizes Human Fibrosarcoma Cells to Oxidative Stress Leading to Cellular Senescence* , 2007, Journal of Biological Chemistry.

[95]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[96]  S. Di Cosimo,et al.  Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  B. Erni,et al.  Synthesis of phosphoenol pyruvate (PEP) analogues and evaluation as inhibitors of PEP-utilizing enzymes. , 2002, European journal of biochemistry.